Medtronic grows, but not as much as expected
This article was originally published in Clinica
Analysts were disappointed by Medtronic on November 17 when the company reported second-quarter net earnings of $536m, against a Thomson First Call analyst consensus projection of $553m. Nevertheless, the profit was up by 13%, on an 11% revenue increase to $2.4bn.
You may also be interested in...
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.